Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Shiels, E. Engels (2017)
Evolving epidemiology of HIV-associated malignanciesCurrent Opinion in HIV and AIDS, 12
I. Lawal, N. Nyakale, L. Harry, Moshe Modiselle, A. Ankrah, A. Msomi, N. Mokgoro, T. Boshomane, C. Wiele, M. Sathekge (2017)
The role of F-18 FDG PET/CT in evaluating the impact of HIV infection on tumor burden and therapy outcome in patients with Hodgkin lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 44
A. Ankrah, A. Glaudemans, H. Klein, R. Dierckx, M. Sathekge (2017)
The Role of Nuclear Medicine in the Staging and Management of Human Immune Deficiency Virus Infection and Associated DiseasesNuclear Medicine and Molecular Imaging, 51
D. Hasenclever, Volker Diehl, J. Armitage, D. Assouline, M. Björkholm, E. Brusamolino, G. Canellos, P. Carde, D. Crowther, David Cunningham, H. Eghbali, Christophe Ferm, R. Fisher, J. Glick, B. Glimelius, P. Gobbi, H. Holte, S. Horning, T. Lister, D. Longo, F. Mandelli, A. Polliack, S. Proctor, L. Specht, J. Sweetenham, G. Hudson (1998)
A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.The New England journal of medicine, 339 21
M. Hleyhel, A. Belot, A. Bouvier, P. Tattevin, J. Pacanowski, P. Genet, N. Castro, J. Berger, C. Dupont, A. Lavolé, C. Pradier, D. Salmon, A. Simon, V. Martinez, D. Costagliola, S. Grabar (2013)
Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 57 11
M. Hentrich, M. Berger, C. Wyen, J. Siehl, J. Rockstroh, Markus Müller, G. Fätkenheuer, E. Seidel, M. Nickelsen, T. Wolf, A. Rieke, D. Schürmann, R. Schmidmaier, M. Planker, J. Alt, F. Mosthaf, A. Engert, K. Arastéh, C. Hoffmann (2012)
Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 33
S. Montoto, Kate Shaw, J. Okosun, Shreyans Gandhi, P. Fields, Andrew Wilson, M. Shanyinde, K. Cwynarski, R. Marcus, J. Vos, A. Young, M. Tenant‐Flowers, C. Orkin, M. Johnson, D. Chilton, J. Gribben, M. Bower (2012)
HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 33
T. Hayashi, S. Yamagami, Kazumi Tanaka, Seiichi Yokoo, T. Usui, S. Amano, N. Mizuki (2008)
A mouse model of allogeneic corneal endothelial cell transplantation.Cornea, 27 6
L. Kostakoglu, S. Chauvie (2018)
Metabolic Tumor Volume Metrics in Lymphoma.Seminars in nuclear medicine, 48 1
J. Radford, T. Illidge, N. Counsell, B. Hancock, R. Pettengell, P. Johnson, J. Wimperis, D. Culligan, B. Popova, Paul Smith, A. McMillan, A. Brownell, A. Kruger, A. Lister, P. Hoskin, M. O'Doherty, S. Barrington (2015)
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.The New England journal of medicine, 372 17
D. Eichenauer, A. Engert, Marc André, Massimo Federico, Timothy Illidge, Martin Hutchings, M. Ladetto (2010)
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 25 Suppl 3
A. Engert, V. Diehl, J. Franklin, A. Lohri, B. Dörken, W. Ludwig, P. Koch, M. Hänel, M. Pfreundschuh, M. Wilhelm, L. Trümper, W. Aulitzky, M. Bentz, M. Rummel, O. Sezer, H. Müller-hermelink, D. Hasenclever, M. Löffler (2009)
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 27
Moo‐Kon Song, J. Chung, Je-Jung Lee, S. Jeong, Sang-min Lee, Jun‐Shik Hong, A. Chong, J. Moon, Jihoon Kim, S. Lee, Seong-Jang Kim, Ho-Jin Shin (2013)
Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphomaCancer Science, 104
G. Faguet (1995)
Hodgkin's disease: basing treatment decisions on prognostic factors.Leukemia & lymphoma, 17 3-4
Á. Mayor, Eduardo Santiago-Rodríguez, E. Ríos-Olivares, G. Tortolero-Luna, R. Hunter-Mellado (2016)
Malignancies Trends in a Hispanic Cohort of HIV Persons in Puerto Rico before and after cART.International journal of cancer research, 12 2
A. Carbone, C. Volpi, A. Gualeni, A. Gloghini (2017)
Epstein–Barr virus associated lymphomas in people with HIVCurrent Opinion in HIV and AIDS, 12
N. Skoetz, A. Will, I. Monsef, C. Brillant, A. Engert, B. Tresckow (2017)
Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.The Cochrane database of systematic reviews, 5
R. Boellaard, R. Delgado-Bolton, W. Oyen, F. Giammarile, K. Tatsch, W. Eschner, F. Verzijlbergen, S. Barrington, L. Pike, W. Weber, S. Stroobants, D. Delbeke, K. Donohoe, Scott Holbrook, M. Graham, G. Testanera, O. Hoekstra, J. Zijlstra, Eric Visser, C. Hoekstra, J. Pruim, A. Willemsen, B. Arends, J. Kotzerke, A. Bockisch, T. Beyer, A. Chiti, B. Krause (2014)
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0European Journal of Nuclear Medicine and Molecular Imaging, 42
B. Xicoy, J. Ribera, P. Miralles, J. Berenguer, R. Rubio, B. Mahíllo, M. Valencia, E. Abella, A. López-Guillermo, A. Sureda, M. Morgades, J. Navarro, H. Esteban (2007)
Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma.Haematologica, 92 2
C. Besson, R. Lancar, S. Prévôt, P. Brice, M. Meyohas, B. Marchou, J. Gabarre, F. Bonnet, C. Goujard, O. Lambotte, F. Boué, N. Mounier, M. Partisani, F. Raffi, R. Costello, H. Hendel‐Chavez, M. Algarte-Genin, S. Trabelsi, L. Marchand, M. Raphael, Y. Taoufik, D. Costagliola (2015)
High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 61 9
M. Shiels, R. Pfeiffer, M. Gail, H. Hall, Jianmin Li, A. Chaturvedi, K. Bhatia, T. Uldrick, R. Yarchoan, J. Goedert, E. Engels (2011)
Cancer burden in the HIV-infected population in the United States.Journal of the National Cancer Institute, 103 9
D. Tseng, L. Rachakonda, Z. Su, R. Advani, S. Horning, R. Hoppe, A. Quon, E. Graves, B. Loo, P. Tran (2012)
Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's diseaseRadiation Oncology (London, England), 7
R. Cobucci, P. Lima, Pollyana Souza, Vanessa Costa, M. Cornetta, J. Fernandes, Ana Gonçalves (2015)
Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review.Journal of infection and public health, 8 1
M. Sorigué, O. García, G. Tapia, M. Baptista, M. Moreno, J. Mate, J. Sancho, E. Feliú, J. Ribera, J. Navarro (2017)
HIV-infection has no prognostic impact on advanced-stage classical Hodgkin lymphoma.AIDS
A. Gallamini, C. Tarella, S. Viviani, A. Rossi, C. Patti, A. Mulé, M. Picardi, A. Romano, M. Cantonetti, G. Nasa, L. Trentin, S. Bolis, D. Rapezzi, R. Battistini, D. Gottardi, P. Gavarotti, P. Corradini, M. Cimminiello, C. Schiavotto, G. Parvis, R. Zanotti, G. Gini, A. Ferreri, P. Viero, M. Miglino, A. Billio, A. Avigdor, A. Biggi, F. Fallanca, U. Ficola, M. Gregianin, A. Chiaravalloti, G. Prosperini, F. Bergesio, S. Chauvie, C. Pavoni, A. Gianni, A. Rambaldi (2018)
Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 5
J. Castillo, M. Bower, J. Brühlmann, U. Novak, H. Furrer, P. Tanaka, C. Besson, S. Montoto, K. Cwynarski, J. Abramson, S. Dalia, M. Bibas, J. Connors, M. Furman, M. Nguyen, T. Cooley, B. Beltrán, J. Collins, J. Vose, B. Xicoy, J. Ribera (2015)
Prognostic factors for advanced‐stage human immunodeficiency virus‐associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi‐institutional retrospective studyCancer, 121
ObjectivesBaseline metabolic metrics on fluorine-18-fluorodeoxyglucose PET (18F-FDG PET) have prognostic value in Hodgkin lymphoma. International Prognostic Score (IPS) is used in the risk stratification of Hodgkin lymphoma. We compared the metabolic indices in HIV-infected and the IPS in HIV-infected and uninfected patients with Hodgkin lymphoma.Patients and methodsWe retrospectively reviewed the data of HIV-infected and HIV-uninfected patients with classic Hodgkin lymphoma who had 18F-FDG PET for staging and compared the maximum standardized uptake value, mean standardized uptake value, metabolic tumor volume, and total lesion glycolysis between the two groups. We also compared the IPS and other prognostic indicators and correlated them with the metabolic indices in the two groups.ResultsWe studied 160 patients, which included 57 patients who were infected with HIV. The mean age was 33.84±11.88 years, with 38% (n=61) being female. The median cluster of differentiation 4 count and HIV viral load were 259 cells/mm3 and 4837.50 copies/ml, respectively. No significant difference in maximum standardized uptake value, mean standardized uptake value, metabolic tumor volume, and total lesion glycolysis between the two groups was found. Among the seven parameters of the IPS, only male sex (HIV-uninfected group higher, P=0.005) and serum albumin less than 4 g/dl were significantly different. The other parameters were not significantly different between the two groups. Other prognostic indicators including bulky disease, extranodal involvement, and the number of nodal groups involved were not significantly different between the two groups.ConclusionThere was no significant difference in 18F-FDG metabolic parameters, IPS, and other risk indicators between HIV-infected and HIV-uninfected patients with Hodgkin lymphoma.
Nuclear Medicine Communications – Wolters Kluwer Health
Published: Nov 1, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.